vs
艾伯维（ABBV）与Cooper Companies (The)（COO）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Cooper Companies (The)的15.6倍（$16.6B vs $1.1B）。艾伯维净利率更高（10.9% vs 7.9%，领先3.0%）。艾伯维同比增速更快（10.0% vs 4.6%）。艾伯维自由现金流更多（$4.9B vs $149.9M）。过去两年艾伯维的营收复合增速更高（16.2% vs 6.9%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
ABBV vs COO — 直观对比
营收规模更大
ABBV
是对方的15.6倍
$1.1B
营收增速更快
ABBV
高出5.5%
4.6%
净利率更高
ABBV
高出3.0%
7.9%
自由现金流更多
ABBV
多$4.7B
$149.9M
两年增速更快
ABBV
近两年复合增速
6.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.1B |
| 净利润 | $1.8B | $84.6M |
| 毛利率 | 72.6% | 61.1% |
| 营业利润率 | 27.3% | 13.2% |
| 净利率 | 10.9% | 7.9% |
| 营收同比 | 10.0% | 4.6% |
| 净利润同比 | 8354.5% | -28.0% |
| 每股收益（稀释后） | $1.02 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVCOO
| Q4 25 | $16.6B | $1.1B | ||
| Q3 25 | $15.8B | $1.1B | ||
| Q2 25 | $15.4B | $1.0B | ||
| Q1 25 | $13.3B | $964.7M | ||
| Q4 24 | $15.1B | $1.0B | ||
| Q3 24 | $14.5B | $1.0B | ||
| Q2 24 | $14.5B | $942.6M | ||
| Q1 24 | $12.3B | $931.6M |
净利润ABBVCOO
| Q4 25 | $1.8B | $84.6M | ||
| Q3 25 | $186.0M | $98.3M | ||
| Q2 25 | $938.0M | $87.7M | ||
| Q1 25 | $1.3B | $104.3M | ||
| Q4 24 | $-22.0M | $117.5M | ||
| Q3 24 | $1.6B | $104.7M | ||
| Q2 24 | $1.4B | $88.9M | ||
| Q1 24 | $1.4B | $81.2M |
毛利率ABBVCOO
| Q4 25 | 72.6% | 61.1% | ||
| Q3 25 | 66.4% | 65.3% | ||
| Q2 25 | 71.8% | 67.8% | ||
| Q1 25 | 70.0% | 68.4% | ||
| Q4 24 | 70.9% | 66.5% | ||
| Q3 24 | 70.9% | 66.1% | ||
| Q2 24 | 70.9% | 67.0% | ||
| Q1 24 | 66.7% | 67.0% |
营业利润率ABBVCOO
| Q4 25 | 27.3% | 13.2% | ||
| Q3 25 | 12.1% | 16.6% | ||
| Q2 25 | 31.7% | 18.4% | ||
| Q1 25 | 28.0% | 18.9% | ||
| Q4 24 | -9.9% | 19.5% | ||
| Q3 24 | 26.5% | 19.2% | ||
| Q2 24 | 27.6% | 17.2% | ||
| Q1 24 | 22.7% | 16.4% |
净利率ABBVCOO
| Q4 25 | 10.9% | 7.9% | ||
| Q3 25 | 1.2% | 9.3% | ||
| Q2 25 | 6.1% | 8.7% | ||
| Q1 25 | 9.6% | 10.8% | ||
| Q4 24 | -0.1% | 11.5% | ||
| Q3 24 | 10.8% | 10.4% | ||
| Q2 24 | 9.5% | 9.4% | ||
| Q1 24 | 11.1% | 8.7% |
每股收益（稀释后）ABBVCOO
| Q4 25 | $1.02 | $0.42 | ||
| Q3 25 | $0.10 | $0.49 | ||
| Q2 25 | $0.52 | $0.44 | ||
| Q1 25 | $0.72 | $0.52 | ||
| Q4 24 | $-0.03 | $0.59 | ||
| Q3 24 | $0.88 | $0.52 | ||
| Q2 24 | $0.77 | $0.44 | ||
| Q1 24 | $0.77 | $0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $110.6M |
| 总债务越低越好 | $58.9B | $2.5B |
| 股东权益账面价值 | $-3.3B | $8.2B |
| 总资产 | $134.0B | $12.4B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ABBVCOO
| Q4 25 | $5.3B | $110.6M | ||
| Q3 25 | $5.7B | $124.9M | ||
| Q2 25 | $6.5B | $116.2M | ||
| Q1 25 | $5.2B | $100.9M | ||
| Q4 24 | $5.6B | $107.6M | ||
| Q3 24 | $7.3B | $109.7M | ||
| Q2 24 | $13.2B | $112.4M | ||
| Q1 24 | $18.1B | $135.2M |
总债务ABBVCOO
| Q4 25 | $58.9B | $2.5B | ||
| Q3 25 | $63.0B | $2.4B | ||
| Q2 25 | $63.0B | $2.5B | ||
| Q1 25 | $64.5B | $2.5B | ||
| Q4 24 | $60.3B | $2.6B | ||
| Q3 24 | $58.5B | $2.6B | ||
| Q2 24 | $58.0B | $2.7B | ||
| Q1 24 | $63.8B | $2.7B |
股东权益ABBVCOO
| Q4 25 | $-3.3B | $8.2B | ||
| Q3 25 | $-2.6B | $8.4B | ||
| Q2 25 | $-183.0M | $8.3B | ||
| Q1 25 | $1.4B | $8.1B | ||
| Q4 24 | $3.3B | $8.1B | ||
| Q3 24 | $6.0B | $7.9B | ||
| Q2 24 | $6.8B | $7.8B | ||
| Q1 24 | $8.0B | $7.7B |
总资产ABBVCOO
| Q4 25 | $134.0B | $12.4B | ||
| Q3 25 | $133.9B | $12.4B | ||
| Q2 25 | $137.2B | $12.4B | ||
| Q1 25 | $136.2B | $12.2B | ||
| Q4 24 | $135.2B | $12.3B | ||
| Q3 24 | $143.4B | $12.1B | ||
| Q2 24 | $141.9B | $12.0B | ||
| Q1 24 | $148.9B | $12.0B |
负债/权益比ABBVCOO
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | 45.44× | 0.31× | ||
| Q4 24 | 18.15× | 0.32× | ||
| Q3 24 | 9.70× | 0.33× | ||
| Q2 24 | 8.56× | 0.34× | ||
| Q1 24 | 7.97× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $247.9M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $149.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 14.1% |
| 资本支出强度资本支出/营收 | 2.0% | 9.2% |
| 现金转化率经营现金流/净利润 | 2.87× | 2.93× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $433.7M |
8季度趋势，按日历期对齐
经营现金流ABBVCOO
| Q4 25 | $5.2B | $247.9M | ||
| Q3 25 | $7.0B | $261.4M | ||
| Q2 25 | $5.2B | $96.2M | ||
| Q1 25 | $1.6B | $190.6M | ||
| Q4 24 | $7.0B | $268.1M | ||
| Q3 24 | $5.4B | $207.5M | ||
| Q2 24 | $2.3B | $111.0M | ||
| Q1 24 | $4.0B | $122.7M |
自由现金流ABBVCOO
| Q4 25 | $4.9B | $149.9M | ||
| Q3 25 | $6.6B | $164.5M | ||
| Q2 25 | $4.9B | $18.1M | ||
| Q1 25 | $1.4B | $101.2M | ||
| Q4 24 | $6.8B | $128.1M | ||
| Q3 24 | $5.2B | $118.5M | ||
| Q2 24 | $2.0B | $36.9M | ||
| Q1 24 | $3.8B | $4.6M |
自由现金流率ABBVCOO
| Q4 25 | 29.4% | 14.1% | ||
| Q3 25 | 42.1% | 15.5% | ||
| Q2 25 | 31.7% | 1.8% | ||
| Q1 25 | 10.5% | 10.5% | ||
| Q4 24 | 44.7% | 12.6% | ||
| Q3 24 | 35.9% | 11.8% | ||
| Q2 24 | 14.0% | 3.9% | ||
| Q1 24 | 31.3% | 0.5% |
资本支出强度ABBVCOO
| Q4 25 | 2.0% | 9.2% | ||
| Q3 25 | 2.4% | 9.1% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 1.8% | 9.3% | ||
| Q4 24 | 1.9% | 13.7% | ||
| Q3 24 | 1.7% | 8.9% | ||
| Q2 24 | 1.7% | 7.9% | ||
| Q1 24 | 1.6% | 12.7% |
现金转化率ABBVCOO
| Q4 25 | 2.87× | 2.93× | ||
| Q3 25 | 37.76× | 2.66× | ||
| Q2 25 | 5.49× | 1.10× | ||
| Q1 25 | 1.27× | 1.83× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | 3.49× | 1.98× | ||
| Q2 24 | 1.66× | 1.25× | ||
| Q1 24 | 2.95× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
